These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36867396)

  • 21. The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006-17): a multicentre, retrospective observational study.
    Agudelo CI; Castañeda-Orjuela C; Brandileone MCC; Echániz-Aviles G; Almeida SCG; Carnalla-Barajas MN; Regueira M; Fossati S; Alarcón P; Araya P; Duarte C; Sánchez J; Novas M; Toraño-Peraza G; Rodríguez-Ortega M; Chamorro-Cortesi G; Kawabata A; García-Gabarrot G; Camou T; Spadola E; Payares D; Andrade AL; Di Fabio JL; Castañeda E;
    Lancet Infect Dis; 2021 Mar; 21(3):405-417. PubMed ID: 32986996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.
    Perdrizet J; Santana CFS; Senna T; Alexandre RF; Sini de Almeida R; Spinardi J; Wasserman M
    Hum Vaccin Immunother; 2021 Apr; 17(4):1162-1172. PubMed ID: 32966176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation.
    Shafie AA; Ahmad N; Naidoo J; Foo CY; Wong C; Pugh S; Tan KK
    Hum Vaccin Immunother; 2020 Jul; 16(7):1719-1727. PubMed ID: 31951782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
    Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR
    Lancet Infect Dis; 2020 Dec; 20(12):1426-1436. PubMed ID: 32857992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
    Sohn HS; Suh DC; Jang E; Kwon JW
    J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis.
    Balsells E; Guillot L; Nair H; Kyaw MH
    PLoS One; 2017; 12(5):e0177113. PubMed ID: 28486544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M; Christopoulou D; Schmitt HJ
    BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study.
    Savulescu C; Krizova P; Lepoutre A; Mereckiene J; Vestrheim DF; Ciruela P; Ordobas M; Guevara M; McDonald E; Morfeldt E; Kozakova J; Varon E; Cotter S; Winje BA; Munoz-Almagro C; Garcia L; Castilla J; Smith A; Henriques-Normark B; Celentano LP; Hanquet G;
    Lancet Respir Med; 2017 Aug; 5(8):648-656. PubMed ID: 28359798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive value assessments for new pediatric pneumococcal conjugate vaccines.
    Hu T; Weiss T; Bencina G; Owusu-Edusei K; Petigara T
    J Med Econ; 2021; 24(1):1083-1086. PubMed ID: 34433365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico.
    Wasserman M; Palacios MG; Grajales AG; Baez/Revueltas FB; Wilson M; McDade C; Farkouh R
    Hum Vaccin Immunother; 2019; 15(3):560-569. PubMed ID: 30156978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease.
    Izurieta P; Nieto Guevara J
    Hum Vaccin Immunother; 2022 Dec; 18(1):1872341. PubMed ID: 33605846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020.
    Maeda H; Gopal Dhoubhadel B; Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
    Vaccine; 2022 Sep; 40(37):5504-5512. PubMed ID: 35963821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Healthcare Costs for Pneumococcal Disease in the Era of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine: A Population-Based Study.
    Vadlamudi NK; Sadatsafavi M; Patrick DM; Rose C; Hoang L; Marra F
    Value Health; 2022 Sep; 25(9):1510-1519. PubMed ID: 35466049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.
    Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
    Hum Vaccin Immunother; 2022 Dec; 18(1):1942712. PubMed ID: 34319865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
    Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
    Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.
    Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK
    Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
    Savulescu C; Krizova P; Valentiner-Branth P; Ladhani S; Rinta-Kokko H; Levy C; Mereckiene J; Knol M; Winje BA; Ciruela P; de Miguel S; Guevara M; MacDonald L; Kozakova J; Slotved HC; Fry NK; Pekka Nuorti J; Danis K; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Sanz JC; Castilla J; Smith A; Colzani E; Pastore Celentano L; Hanquet G;
    Vaccine; 2022 Jun; 40(29):3963-3974. PubMed ID: 35637067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
    Shirley M
    Drugs; 2022 Jun; 82(9):989-999. PubMed ID: 35793027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
    Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
    PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.